Japan’s PMDA Collecting Adverse Event Reports Directly From Patients
This article was originally published in PharmAsia News
Executive Summary
Japan's pharmaceutical regulatory agency says its pilot program for patient reports on adverse drug reactions has been running smoothly with minor changes underway.
You may also be interested in...
Japan’s 2014 Drug Price Reforms Extend Price Premium Program
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.
Revised Rules For Japan’s Medical Devices Could Mean Speedier Time To Market
New rules separate medical devices from pharma regulations to provide clarity and regulatory efficiency, removing approval hurdles for devices and software in 2014.
Novartis Launches Japan Compliance Advisory Board In Wake Of Diovan Turmoil
Novartis Pharma in Japan established a compliance advisory board as part of a move to salvage its tarnished image with ongoing Diovan scandals.